We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

115 hedge funds and large institutions have $757M invested in Avidity Biosciences in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

173,100% more call options, than puts

Call options by funds: $3.46M | Put options by funds: $2K

280% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 5

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

12% more funds holding

Funds holding: 103 → 115 (+12)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.12% less ownership

Funds ownership: 106.91% → 104.79% (-2.1%)

30% less capital invested

Capital invested by funds: $1.09B → $757M (-$328M)

Holders
115
Holders Change
+12
Holders Change %
+11.65%
% of All Funds
1.94%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
44
Reduced
19
Closed
5
Calls
$3.46M
Puts
$2K
Net Calls
+$3.46M
Net Calls Change
+$747K

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$33.7M
2
BlackRock
BlackRock
New York
+$9.9M
3
Artisan Partners
Artisan Partners
Wisconsin
+$5.85M
4
State Street
State Street
Massachusetts
+$2.91M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.78M

Top Sellers

Rank Fund Capital Flow
1
AWA
Aaron Wealth Advisors
Illinois
-$56.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.52M
3
ACM
Altium Capital Management
New York
-$1.38M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$1M
5
ACM
Alethea Capital Management
Washington
-$811K
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
26
Walleye Capital
New York
$3.96M +$1.97M +132,671 +95%
AllianceBernstein
27
AllianceBernstein
Tennessee
$3.96M +$1.94M +130,280 +92%
Marshall Wace
28
Marshall Wace
United Kingdom
$3.85M – – –
AG
29
Artal Group
Luxembourg
$3.63M – – –
AWA
30
Aaron Wealth Advisors
Illinois
$3.13M -$56.1M -3,769,152 -95%
CS
31
Candriam SCA
Luxembourg
$3.07M +$760K +51,079 +32%
Balyasny Asset Management
32
Balyasny Asset Management
Illinois
$2.71M +$2.78M +186,702 New
N
33
Nuveen
North Carolina
$2.67M +$1.05M +70,506 +62%
Goldman Sachs
34
Goldman Sachs
New York
$2.66M +$913K +61,391 +50%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$2.28M +$300K +20,133 +15%
ACM
36
Altium Capital Management
New York
$2.18M -$1.38M -93,000 -38%
Morgan Stanley
37
Morgan Stanley
New York
$1.95M +$370K +24,857 +23%
TD Asset Management
38
TD Asset Management
Ontario, Canada
$1.93M -$158K -10,615 -7%
Barclays
39
Barclays
United Kingdom
$1.89M +$1.17M +78,709 +153%
JP Morgan Chase
40
JP Morgan Chase
New York
$1.84M +$379K +25,467 +25%
US Bancorp
41
US Bancorp
Minnesota
$1.83M +$846K +56,865 +82%
Deutsche Bank
42
Deutsche Bank
Germany
$1.82M +$36.3K +2,442 +2%
Renaissance Technologies
43
Renaissance Technologies
New York
$1.57M +$1.04M +69,900 +182%
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.32M +$146K +9,835 +12%
TCM
45
Tekla Capital Management
Massachusetts
$1.24M +$874K +58,766 +222%
Swiss National Bank
46
Swiss National Bank
Switzerland
$1.21M – – –
Wells Fargo
47
Wells Fargo
California
$1.2M +$22.8K +1,535 +2%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$1.01M +$346K +23,249 +50%
Citigroup
49
Citigroup
New York
$817K +$425K +28,583 +103%
Bank of America
50
Bank of America
North Carolina
$792K +$176K +11,846 +28%
1
2
3 4 5

RNAM Hedge Fund Activity: Q2 2022 in Review

115 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2022, worth a combined $757M — down 30% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RNAM positions and 5 closed out — a net gain of 14 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Cowen and Company, opening a new position worth an estimated $33.7M. The largest seller was Aaron Wealth Advisors, cutting an estimated $56.1M.

  • 115 institutional investors held Avidity Biosciences (RNAM) as of Q2 2022, up from 103 in Q1 2022.
  • Funds reported $757M of Avidity Biosciences stock for Q2 2022, down 30% quarter-over-quarter.
  • 19 funds opened new Avidity Biosciences positions in Q2 2022 and 5 closed out, a net change of +14 holders.
  • The largest Avidity Biosciences buyer in Q2 2022 was Cowen and Company, an estimated $33.7M added.
  • The largest Avidity Biosciences seller in Q2 2022 was Aaron Wealth Advisors, an estimated $56.1M sold.

Based on aggregated 13F filings for Q2 2022.